相关实验视频
Updated: Sep 19, 2025

23:53
Ole Isacson: Development of New Therapies for Parkinson's Disease
Published on: April 29, 2007
8.1K
对患有帕金森病的老年患者的治疗
Marija Djukic1, Elisabeth Yoshida-Stiksrud, Roland Nau
1Geriatric Center, Protestant Hospital Göttingen-Weende, Göttingen; Institute for Neuropathology, University Medical Center Göttingen, Göttingen.
Deutsches Arzteblatt international
|June 4, 2025
概括
通过优化药物和疗法,简化老年人的帕金森病治疗. 本综述提供了切实可行的策略,以减少副作用,并改善患者和护理人员的管理.
科学领域:
- 老年神经学 老年神经学
- 运动障碍 运动障碍
- 药物治疗 药物治疗
背景情况:
- 帕金森病影响了超过80岁的15万名德国人,其中80%患有痴呆症.
- 老年帕金森病患者往往具有多病症,使治疗选择复杂化.
- 这种人口在抗帕金森症药物的临床试验中表现不足.
研究的目的:
- 提出简化老年帕金森病患者治疗方案的实际方法.
- 为了减少副作用,并提高患者和护理人员的治疗可控性.
主要方法:
- 对老年人帕金森病当前治疗策略的叙述性综述.
- 专注于简化药物治疗计划,并纳入支持性疗法.
主要成果:
- 主要治疗方法是配合dopa脱酶抑制剂的levodopa;建议在夜间延长释放.
- 其他抗帕金森症药物应节制使用. 在严重波动的情况下,请考虑阴性Levodopa或皮下Foslevodopa.
- 里瓦斯蒂格明用于帕金森病痴呆症;奎平或克洛扎平用于精神病. 物理和语言治疗是至关重要的.
结论:
- 对于老年帕金森病患者的基于证据的治疗,需要进一步的研究和随机对照试验.
- 量身定制的临床试验对于改善这种人群的治疗策略至关重要.
相关概念视频
Parkinson's Disease: Treatment
391
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
391
Parkinson's Disease: Overview
723
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
723
Alzheimer's Disease: Treatment
265
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
265
Drug Therapy
107
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
107
Psychosis: Goals of Pharmacotherapy
216
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
216
Peripheral Artery Disease III: Interprofessional Care
35
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
35

